Lymph node ratio as an alternative to pN staging in node-positive breast cancer

Journal of Clinical Oncology

Volumn 27, Issue 7, 2009, Pages 1062-1068

  Vinh Hung, Vincent ^a   Verkooijen, Helena M ^a   Fioretta, Gerald ^a   Neyroud Caspar, Isabelle ^a   Rapiti, Elisabetta ^a   Vlastos, Georges ^a   Deglise, Carole ^a   Usel, Massimo ^a   Lutz, Jean Miche ^a   Bouchardy, Christine ^a  

^a GENEVA CANCER REGISTRY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; FEMALE; HIGH RISK POPULATION; HUMAN; LYMPH NODE DISSECTION; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE;

AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; LIKELIHOOD FUNCTIONS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 61449117823     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.6965     Document Type: Article

References (60)

1. Fitzgibbons PL, Page DL, Weaver D, et al: Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966-978, 2000
2. Vinh-Hung V, Burzykowski T, Cserni G, et al: Functional form of the effect of the numbers of axillary nodes on survival in early breast cancer. Int J Oncol 22:697-704, 2003
3. Hudis CA, Seidman AD, Baselga J, et al: Sequential adjuvant therapy with doxorubicin/pacli-taxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Semin Oncol 22:18-23, 1995
4. Gianni AM, Siena S, Bregni M, et al: Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results. J Clin Oncol 15:2312-2321, 1997
5. Fountzilas G, Nicolaides C, Aravantinos G, et al: Dose-dense adjuvant chemotherapy with epiru-bicin monotherapy in patients with operable breast cancer and >/=10 positive axillary lymph nodes: A feasibility study. Oncology 55:508-512, 1998
6. Singletary SE, Allred C, Ashley P, et al: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628-3636, 2002
7. Greene FL, Page DL, Fleming ID, et al: AJCC Cancer Staging Handbook (6th ed). New York, NY, Springer Verlag, 2002, pp 255-281
8. Sobin LH, Wittekind Ch (eds): TNM Classification of Malignant Tumours (ed 6). NewYork, NY, Wiley, 2002, pp 131-141
9. Vinh-Hung V, Verschraegen C, Promish DI, et al: Ratios of involved nodes in early breast cancer. Breast Cancer Res 6:R680-R688, 2004
10. Woodward WA, Vinh-Hung V, Ueno NT, et al: Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol 24:2910-2916, 2006
11. Truong PT, Woodward WA, Thames HD, et al: The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: An analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 68:59-65, 2007
12. Bouchardy C: Switzerland, Geneva, in Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (eds): Cancer Incidence in Five Continents (vol VII). Lyon, France, International Agency for Research on Cancer, 1997, pp 666-669
13. World Health Organization: ICD-O International Classification of Diseases for Oncology (ed 1). Geneva, Switzerland, World Health Organization, 1976
14. Tableman M, Kim JS: Survival Analysis Using S: Analysis of Time-to-Event Data. Boca Raton, FL, Chapman & Hall, 2003
15. Vinh-Hung V, Vlastos G, Fioretta G, et al: Nodal ratios as an alternative to pN-staging in node-positive breast cancer: A validation study. Breast Cancer Res Treat 106:S215, 2007 (suppl, abstr 5027)
16. Gong G: Cross-validation, the jackknife, and the bootstrap: Excess error estimation in forward logistic regression. J Am Stat Assoc 81:108-113, 1986
17. The R Foundation for Statistical Computing: The R project for statistical computing: The Comprehensive R Archive Network (CRAN) 2008. http://www.r-project.org/
18. Venables WN, Ripley BD: Modern Applied Statistics with S (ed 4). New York, NY, Springer-Verlag, 2002, pp 172-176
19. Wood SN: Generalized Additive Models: An Introduction with R. Boca Raton, FL, Chapman & Hall/CRC Press, 2006
20. Voordeckers M, Vinh-Hung V, Van de Steene J, et al: The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol 70: 225-230, 2004
21. Kuru B: Prognostic significance of total number of nodes removed, negative nodes removed, and ratio of positive nodes to removed nodes in node positive breast carcinoma. Eur J Surg Oncol 32:1082-1088, 2006
22. Yildirim E, Berberoglu U: Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients. World J Surg 31:276-289, 2007
23. Greenstein AJ, Litle VR, Swanson SJ, et al: Prognostic significance of the number of lymph node metastases in esophageal cancer. J Am Coll Surg 206:239-246, 2008
24. Vlastos AT, Vlastos G, De Ridder M, et al: Prognostic importance of nodal involvement in vul-var carcinoma (VC). Int J Gynecol Cancer 16:732-733, 2006 (suppl 3, abstr 0469)
25. De Ridder M, Vinh-Hung V, Van Nieuwenhove Y, et al: Prognostic value of the lymph node ratio in node positive colon cancer. Gut 55:1681, 2006
26. Chan JK, Kapp DS, Cheung MK, et al: The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients. Br J Cancer 97:605-611, 2007
27. Siewert JR, Bottcher K, Stein HJ, et al: Relevant prognostic factors in gastric cancer: Ten-year results of the German Gastric Cancer Study. Ann Surg 228:449-461, 1998
28. Hyung WJ, Noh SH, Yoo CH, et al: Prognostic significance of metastatic lymph node ratio in T3 gastric cancer. World J Surg 26:323-329, 2002
29. Berger AC, Watson JC, Ross EA, et al: The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenec-tomy for pancreatic adenocarcinoma. Am Surg 70: 235-240, 2004
30. Herr HW: Superiority of ratio based lymph node staging for bladder cancer. J Urol 169:943-945, 2003
31. Tsuchiya A, Kanno M, Abe R: The impact of lymph node metastases on the survival of breast cancer patients with ten or more positive lymph nodes. Surg Today 27:902-906, 1997
32. Walker MJ, Osborne MD, Young DC, et al: The natural history of breast cancer with more than 10 positive nodes. Am J Surg 169:575-579, 1995
33. Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in high-risk premeno-pausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337:949-955, 1997
34. Grills IS, Kestin LL, Goldstein N, et al: Risk factors for regional nodal failure after breast-conserving therapy: Regional nodal irradiation reduces rate of axillary failure in patients with four or more positive lymph nodes. Int J Radiat Oncol Biol Phys 56:658-670, 2003
35. Knoop AS, Bentzen SM, Nielsen MM, et al: Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 19:3376-3384, 2001
36. Gürkaynak M, Yildiz F, Atahan IL: T3N0M0 Breast cancer patients: A subgroup with favorable prognosis. Turk J Cancer 33:144-149, 2003 http://www.turkjcancer.org/pdf/pdf-TJC-346.pdf
37. Germain I, Fortin A, Dagnault A, et al: The value of the number of nodes removed (or the ratio of involved nodes) as a prognostic factor in breast cancer. Proc Am Soc Clin Oncol 23:29, 2004 (abstr 611)
38. Hollander N, Schumacher M: On the problem of using 'optimal' cutpoints in the assessment of quantitative prognostic factors. Onkologie 24:194-199, 2001
39. Good PI: Resampling Methods: A Practical Guide to Data Analysis (ed 3). Boston, MA, Birkhauser, 2006
40. Guern AS, Vinh-Hung V: [Statistical distribution of involved axillary lymph nodes in breast cancer]. Bull Cancer 95:449-455, 2008
41. Fedorov V, Mannino F, Zhang R: Consequences of dichotomization. Pharm Stat [epub ahead of print on April 3, 2008]
42. Harrell FE Jr: Problems Caused by Categorizing Continuous Variables. Nashville, TN, Department of Biostatistics, Vanderbilt University, 2008. http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/Cat Continuous
43. Austin PC, Brunner LJ: Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses. Stat Med 23:1159-1178, 2004
44. Morgan TM, Elashoff RM: Effect of categorizing a continuous covariate on the comparison of survival time. J Am Stat Assoc 81:917-921, 1986
45. Schmoor C, Schumacher M: Effects of covari-ate omission and categorization when analysing randomized trials with the Cox model. Stat Med 16:225-237, 1997
46. Taylor JMG, Yu M: Bias and efficiency loss due to categorizing an explanatory variable. J Multi-var Anal 83:248-263, 2002
47. Cserni G, Burzykowski T, Vinh-Hung V, et al: Axillary sentinel node and tumour-related factors associated with non-sentinel node involvement in breast cancer. Jpn J Clin Oncol 34:519-524, 2004
48. Farshid G, Pradhan M, Kollias J, et al: A decision aid for predicting non-sentinel node involve-
49. ment in women with breast cancer and at least one positive sentinel node. Breast 13:494-501, 2004
50. Goyal A, Douglas-Jones A, Newcombe RG, et al: Predictors of non-sentinel lymph node metastasis in breast cancer patients. Eur J Cancer 40:1731-1737, 2004
51. Menes TS, Tartter PI, Mizrachi H, et al: Breast cancer patients with pN0(i+) and pN1(mi) sentinel nodes have high rate of nonsentine node metasta-ses. J Am Coll Surg 200:323-327, 2005
52. Barranger E, Coutant C, Flahault A, et al: An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat 91:1 13-119, 2005
53. Chagpar AB, Scoggins CR, Martin RC, et al: Prediction of sentinel lymph node-only disease in women with invasive breast cancer. Am J Surg 192:882-887, 2006
54. Wada N, Imoto S, Yamauchi C, et al: Predictors of tumour involvement in remaining axillary lymph nodes of breast cancer patients with positive sentinel lymph node. Eur J Surg Oncol 32:29-33, 2006
55. Dauphine CE, Haukoos JS, Vargas MP, et al: Evaluation of three scoring systems predicting non sentinel node metastasis in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 14:1014-1019, 2007
56. van Deurzen CH, van HR, Hobbelink MG, et al: Predictive value of tumor load in breast cancer sentinel lymph nodes for second echelon lymph node metastases. Cell Oncol 29:497-505, 2007
57. Pal A, Provenzano E, Duffy SW, et al: A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg 95:302-309, 2008
58. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
59. Braun S, Naume B: Circulating and disseminated tumor cells. J Clin Oncol 23:1623-1626, 2005
60. Pachmann K, Camara O, Kavallaris A, et al: Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 26:1208-1215, 2008